The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
Recruiting
Observational Study
Multiple Myeloma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 458 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Patients must meet all of the following inclusion criteria.
* Newly diagnosed multiple myeloma patients.
* Patients without any previous anti-myeloma treatment.
* Age: 18-80years old (adult).
* No history of cancer.
* Informed consent.
Exclusion Criteria:
Patients meeting any…
Contacts